 double-blind trial mazindol duchenn dystrophi evid growth hormon progress weak duchenn dystrophi control trial mazindol put growth hormon secret inhibitor boy duchenn dystrophi muscl strength contractur function abil pulmonari function baselin month treatment mazindol mg/d placebo studi power slow expect rate progress weak strength point studi side effect attribut decreas appetit dri mouth behavior chang gastrointestin symptom mazindol dosag patient effect mazindol GH secret postabsorpt igf-i level month mazindol placebo group mazindol-tr patient weight height placebo-tr patient signific effect igf-i level mazindol progress weak duchenn dystrophi